Form 4 for IRON Disc Medicine, Inc.
Accepted 2026-06-18 16:43:40 ET · period of report 2026-06-16 · accession 0001193125-26-275996 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-18 16:43 | 2026-06-16 | IRON | Yu Jonathan Yen-Wen | COO | M - OptEx | $9.86 | +18.6K | 72.9K | +34% | +$183.5K |
| DMT | 2026-06-18 16:43 | 2026-06-16 | IRON | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $69.19 | -18.6K | 54.3K | -26% | -$1.29M |
| DMT | 2026-06-18 16:43 | 2026-06-16 | IRON | Yu Jonathan Yen-Wen | COO | M - OptEx | $0.00 | -18.6K | 32.0K | -37% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-16 | M | A | 5,261 | $9.86 | 59,585 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. |
| 2 | Common | Common Stock | 2026-06-16 | M | A | 13,351 | $9.86 | 72,936 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. |
| 3 | Common | Common Stock | 2026-06-16 | S | D | 11,651 | $68.76 | 61,285 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 to $69.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. |
| 4 | Common | Common Stock | 2026-06-16 | S | D | 6,961 | $69.92 | 54,324 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.40 to $70.19, inclusive. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-06-16 | M | D | 5,261 | $0.00 | 1,753 | D | $9.86 · — to 2031-09-13 | 5,261 Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. (F4) The shares underlying this option are fully vested and exercisable as of the date hereof. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-06-16 | M | D | 13,351 | $0.00 | 31,951 | D | $9.86 · — to 2031-09-13 | 13,351 Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026. (F4) The shares underlying this option are fully vested and exercisable as of the date hereof. |